Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils

Blood

Volumn 115, Issue 4, 2010, Pages 783-791

  Kang, Elizabeth M ^a   Choi, Uimook ^a   Theobald, Narda ^a   Linton, Gilda ^a   Long Priel, Debra A ^b   Kuhns, Doug ^b   Malech, Harry L ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; BUSULFAN; CASPOFUNGIN; FLUCYTOSINE; LINEZOLID; MEROPENEM; MICAFUNGIN; OXIDOREDUCTASE; PALIFERMIN; POSACONAZOLE; RAPAMYCIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT KERATINOCYTE GROWTH FACTOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; RETROVIRUS VECTOR; VANCOMYCIN; VORICONAZOLE; CYBB PROTEIN, HUMAN; MEMBRANE PROTEIN; MYELOABLATIVE AGENT; OXIDIZING AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE;

ADD ON THERAPY; ADULT; APHERESIS; AREA UNDER THE CURVE; ARTICLE; BLOOD; CASE REPORT; CHEST WALL INFECTION; CHRONIC GRANULOMATOUS DISEASE; CLINICAL TRIAL; DIET SUPPLEMENTATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; ENZYME ACTIVITY; GENE THERAPY; HUMAN; LIVER ABSCESS; LOADING DRUG DOSE; LONG TERM CARE; LUNG ASPERGILLOSIS; LUNG INFECTION; MALE; MARKER GENE; MOLONEY LEUKEMIA ONCOVIRUS; MUCOSA INFLAMMATION; MYCOSIS; NEUTROPENIA; NEUTROPHIL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; X CHROMOSOME LINKED DISORDER; X LINKED CHRONIC GRANULOMATOUS DISEASE; ASPERGILLOSIS; AUTOTRANSPLANTATION; ENZYMOLOGY; GENETIC TRANSDUCTION; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; METABOLISM; METHODOLOGY; MONOCYTE; MULTIMODALITY CANCER THERAPY; PHYSIOLOGY; RESPIRATORY BURST; STAPHYLOCOCCUS INFECTION; X CHROMOSOME;

ADULT; ASPERGILLOSIS; BUSULFAN; CHROMOSOMES, HUMAN, X; COMBINED MODALITY THERAPY; GENE THERAPY; GRANULOMATOUS DISEASE, CHRONIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MOLONEY MURINE LEUKEMIA VIRUS; MONOCYTES; MYELOABLATIVE AGONISTS; NADPH OXIDASE; NEUTROPENIA; NEUTROPHILS; OXIDANTS; RESPIRATORY BURST; STAPHYLOCOCCAL INFECTIONS; SUPEROXIDES; THROMBOCYTOPENIA; TRANSDUCTION, GENETIC; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 77949327872     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-05-222760     Document Type: Article

References (45)

1. Winkelstein JA, Marino MC, Johnston RB Jr, et al. Chronic granulomatous disease: report on a national registry of 368 patients. Medicine (Baltimore). 2000;79(3):155-169. (Pubitemid 30327530)
2. Segal BH, Leto TL, Gallin JI, Malech HL, Holland SM. Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine (Baltimore). 2000;79(3):170-200. (Pubitemid 30327531)
3. Mardiney M 3rd, Jackson SH, Spratt SK, Li F, Holland SM, Malech HL. Enhanced host defense after gene transfer in the murine p47phox-deficient model of chronic granulomatous disease. Blood. 1997;89(7):2268-2275.
4. Dinauer MC, Li LL, Bjorgvinsdottir H, Ding C, Pech N. Long-term correction of phagocyte NADPH oxidase activity by retroviral-mediated gene transfer in murine X-linked chronic granulomatous disease. Blood. 1999;94(3):914-922. (Pubitemid 29361822)
5. Sokolic RA, Sekhsaria S, Sugimoto Y, et al. A bicistronic retrovirus vector containing a picornavirus internal ribosome entry site allows for correction of X-linked CGD by selection for MDR1 expression. Blood. 1996;87(1):42-50. (Pubitemid 26011818)
6. Sekhsaria S, Gallin JI, Linton GF, Mallory RM, Mulligan RC, Malech HL. Peripheral blood progenitors as a target for genetic correction of p47phox-deficient chronic granulomatous disease. Proc Natl Acad Sci U S A. 1993;90(16): 7446-7450.
7. Li F, Linton GF, Sekhsaria S, et al. CD34+ peripheral blood progenitors as a target for genetic correction of the two flavocytochrome b558 defective forms of chronic granulomatous disease. Blood. 1994;84(1):53-58. (Pubitemid 24193804)
8. Kiem HP, Andrews RG, Morris J, et al. Improved gene transfer into baboon marrow repopulating cells using recombinant human fibronectin fragment CH-296 in combination with interleukin-6, stem cell factor, FLT-3 ligand, and megakaryocyte growth and development factor. Blood. 1998; 92(6):1878-1886. (Pubitemid 28446676)
9. Tisdale JF, Hanazono Y, Sellers SE, et al. Ex vivo expansion of genetically marked rhesus peripheral blood progenitor cells results in diminished long-term repopulating ability. Blood. 1998;92(4): 1131-1141. (Pubitemid 28369025)
10. Wolach B, Scharf Y, Gavrieli R, de Boer M, Roos D. Unusual late presentation of X-linked chronic granulomatous disease in an adult female with a somatic mosaic for a novel mutation in CYBB. Blood. 2005;105(1):61-66. (Pubitemid 40053064)
11. Kang EM, Hanazano Y, Frare P, et al. Persistent low-level engraftment of rhesus peripheral blood progenitor cells transduced with the fanconi anemia c gene after conditioning with low-dose irradiation. Mol Ther. 2001;3(6):911-919. (Pubitemid 32611301)
12. Rosenzweig M, MacVittie TJ, Harper D, et al. Efficient and durable gene marking of hematopoietic progenitor cells in nonhuman primates after nonablative conditioning. Blood. 1999;94(7): 2271-2286. (Pubitemid 29467675)
13. Malech HL, Horwitz ME, Linton GF, et al. Extended production of oxidase normal neutrophils in X-linked chronic granulomatous disease (CGD) following gene therapy with gp91phos transduced CD34+ cells. Blood. 1998;92[suppl 10]:690a.
14. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease [comments]. Science. 2000;288(5466):669-672. (Pubitemid 30241569)
15. Hacein-Bey-Abina S, Le Deist F, Carlier F, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med. 2002;346(16):1185-1193.
16. Aiuti A, Slavin S, Aker M, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 2002; 296(5577):2410-2413.
17. Ott MG, Schmidt M, Schwarzwaelder K, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. 2006;12(4):401-409.
18. Lutzko C, Kruth S, Abrams-Ogg AC, et al. Genetically corrected autologous stem cells engraft, but host immune responses limit their utility in canine alpha-L-iduronidase deficiency. Blood. 1999; 93(6):1895-1905. (Pubitemid 29128491)
19. Malech HL, Maples PB, Whiting-Theobald N, et al. Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci U S A. 1997;94(22):12133-12138. (Pubitemid 27467855)
20. Schmidt M, Schwarzwaelder K, Bartholomae C, et al. High-resolution insertion-site analysis by linear amplification-mediated PCR (LAM-PCR). Nat Methods. 2007;4(12):1051-1057.
21. Aiuti A, Cattaneo F, Galimberti S, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med. 2009;360(5): 447-458.
22. Kang EM, Hsieh MM, Metzger M, et al. Busulfan pharmacokinetics, toxicity, and low-dose conditioning for autologous transplantation of genetically modified hematopoietic stem cells in the rhesus macaque model. Exp Hematol. 2006;34(2): 132-139. (Pubitemid 43184318)
23. Kahl CA, Tarantal AF, Lee CI, et al. Effects of busulfan dose escalation on engraftment of infant rhesus monkey hematopoietic stem cells after gene marking by a lentiviral vector. Exp Hematol. 2006;34(3):369-381.
24. Klug CA, Cheshier S, Weissman IL. Inactivation of a GFP retrovirus occurs at multiple levels in long-term repopulating stem cells and their differentiated progeny. Blood. 2000;96(3):894-901. (Pubitemid 30616853)
25. Sadat MA, Pech N, Saulnier S, et al. Long-term high-level reconstitution of NADPH oxidase activity in murine X-linked chronic granulomatous disease using a bicistronic vector expressing gp91phox and a Delta LNGFR cell surface marker. Hum Gene Ther. 2003;14(7):651-666. (Pubitemid 36543437)
26. Ryu BY, Evans-Galea MV, Gray JT, Bodine DM, Persons DA, Nienhuis AW. An experimental system for the evaluation of retroviral vector design to diminish the risk for proto-oncogene activation. Blood. 2008;111(4):1866-1875.
27. Evans-Galea MV, Wielgosz MM, Hanawa H, Srivastava DK, Nienhuis AW. Suppression of clonal dominance in cultured human lymphoid cells by addition of the cHS4 insulator to a lentiviral vector. Mol Ther. 2007;15(4):801-809. (Pubitemid 46432001)
28. Bodine DM, Dunbar CE, Girard LJ, et al. Improved amphotropic retrovirus-mediated gene transfer into hematopoietic stem cells. Ann NY Acad Sci. 1998;850:139-150. (Pubitemid 28369755)
29. Dunbar CE, Seidel NE, Doren S, et al. Improved retroviral gene transfer into murine and Rhesus peripheral blood or bone marrow repopulating cells primed in vivo with stem cell factor and granulocyte colony-stimulating factor. Proc Natl Acad Sci U S A. 1996;93(21):11871-11876. (Pubitemid 26347216)
30. Josephson NC, Vassilopoulos G, Trobridge GD, et al. Transduction of human NOD/SCID-repopulating cells with both lymphoid and myeloid potential by foamy virus vectors. Proc Natl Acad Sci U S A. 2002;99(12):8295-8300. (Pubitemid 34651046)
31. Roesler J, Brenner S, Bukovsky AA, et al. Third-generation, self-inactivating gp91(phox) lentivector corrects the oxidase defect in NOD/SCID mouse-repopulating peripheral blood-mobilized CD34+ cells from patients with X-linked chronic granulomatous disease. Blood. 2002;100(13): 4381-4390. (Pubitemid 35429676)
32. Chen LE, Minkes RK, Shackelford PG, Strasberg SM, Kuo EY, Langer JC. Cut it out: managing hepatic abscesses in patients with chronic granulomatous disease. J Pediatr Surg. 2003;38(5):709-713.
33. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003;302(5644):415-419. (Pubitemid 37296260)
34. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2003;348(3):255-256.
35. Davé UP, Jenkins NA, Copeland NG. Gene therapy insertional mutagenesis insights. Science. 2004;303(5656):333.
36. Hematti P, Hong B-K, Ferguson C, et al. Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells. PLoS Biol. 2004;2(12):e423.
37. Shou Y, Ma Z, Lu T, Sorrentino BP. Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy. Proc Natl Acad Sci U S A. 2006;103(31):11730-11735. (Pubitemid 44182519)
38. Woods N-B, Bottero V, Schmidt M, von Kalle C, Verma IM. Gene therapy: therapeutic gene causing lymphoma. Nature. 2006;440(7088):1123.
39. Gaspar HB, Bjorkegren E, Parsley K, et al. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild p;reconditioning. Mol Ther. 2006;14(4):505-513. (Pubitemid 44339393)
40. Calmels B, Ferguson C, Laukkanen MO, et al. Recurrent retroviral vector integration at the MDS1-EVI1 locus in non-human primate hematopoietic cells. Blood. 2005;106(7):2530-2533. (Pubitemid 41510830)
41. Kiem HP, Sellers S, Thomasson B, et al. Long-term clinical and molecular follow-up of large animals receiving retrovirally transduced stem and progenitor cells: no progression to clonal hematopoiesis or leukemia. Mol Ther. 2004;9(3):389-395.
42. Bianchi M, Hakkim A, Brinkmann V, et al. Restoration of NET formation by gene therapy in CGD controls aspergillosis. Blood. 2009;114(13):2619-2622.
43. Naumann N, De Ravin SS, Choi U, et al. Simian immunodeficiency virus lentivector corrects human X-linked chronic granulomatous disease in the NOD//SCID mouse xenograft. Gene Ther. 2007;14(21):1513-1524. (Pubitemid 47570710)
44. + cells. Blood. 2003; 102(8):2789-2797.
45. Green BJ, Lee CS, Rasko JE. Biodistribution of the RD114/mammalian type D retrovirus receptor, RDR. J Gene Med. 2004;6(3):249-259.